BMO Capital Starts Nightstar Therapeutics (NITE) at Outperform
Get Alerts NITE Hot Sheet
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
BMO Capital initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $30.00.
Analyst Matt Luchini believes the NSR-REP1 drug could transform the treatment of choroideremia and forecasts a market opportunity of $710 million. The analyst also sees upside from the company second gene therapy program NSR-RPGR for XLP which could see a peak sales opportunity of $675 million.
For an analyst ratings summary and ratings history on Nightstar Therapeutics click here. For more ratings news on Nightstar Therapeutics click here.
Shares of Nightstar Therapeutics closed at $19.00 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Resumes EQT Corp. (EQT) at Hold
- B.Riley Resumes QuinStreet, Inc. (QNST) at Buy
- Alpine Income Property Trust (PINE) PT Lowered to $18 at Jones Trading
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!